BioLargo, Inc.
BLGO
$0.18
$0.013.94%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -60.28% | -15.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -60.28% | -15.05% | |||
| Cost of Revenue | -46.09% | -23.86% | |||
| Gross Profit | -73.82% | -4.50% | |||
| SG&A Expenses | 158.07% | 5.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 80.89% | -10.76% | |||
| Operating Income | -298.45% | 3.22% | |||
| Income Before Tax | -284.91% | 2.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -284.91% | 2.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 10.87% | -9.92% | |||
| Net Income | -443.54% | -3.20% | |||
| EBIT | -298.45% | 3.22% | |||
| EBITDA | -301.01% | 1.22% | |||
| EPS Basic | -438.46% | -2.63% | |||
| Normalized Basic EPS | -662.50% | -14.29% | |||
| EPS Diluted | -438.46% | -2.63% | |||
| Normalized Diluted EPS | -662.50% | -14.29% | |||
| Average Basic Shares Outstanding | 1.91% | 0.64% | |||
| Average Diluted Shares Outstanding | 1.91% | 0.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||